Immatics Biotechnologies
Germany - MunichBiotechnology
Focus: Immatics Biotechnologies is a Munich-based biotech company specializing in personalized T-cell directed immunotherapies, with a focused oncology pipeline in early-to-mid clinical development.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
Open Jobs
3
Should You Work at Immatics Biotechnologies?
AI assessmentBest suited for scientists and operators seeking early-stage innovation ownership in personalized immunotherapy, but career growth and stability are dependent on undisclosed funding and partnership developments.
Why Work Here
- Access to cutting-edge TCR-based and personalized immunotherapy technology with recent Nature publication validation (May 2026)
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
glioblastoma multiforme multipeptide vaccine IMA950
Brain and Central Nervous System TumorsClinical Trials (1)
NCT01222221Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1Help build intelligence for Immatics Biotechnologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.